Table 1.
PD | Cancer | P Value | |
---|---|---|---|
Age (mean ± SD, range) | 67.6 ± 9.1 (38–87) | 62.9 ± 11.8 (26–79) | 0.02 |
Gender (N; % male) | 64 male (71.1) | 31 male (66.0) | 0.53 |
Level of education (years; mean ± SD) | 16.1 ± 2.9 | 14.8 ± 2.9 | 0.01 |
Income: < | 0.29 | ||
$10,000/year (N; %) | 14 (15.6) | 7 (14.9) | |
$10–20,000/year | 9 (10.0) | 11 (23.4) | |
$20–35,000/year | 10 (11.1) | 6 (12.8) | |
$35–50,000/year | 16 (17.8) | 6 (12.8) | |
$50–100,000/year | 28 (31.1) | 9 (19.2) | |
>$100,000/year | 13 (14.4) | 8 (17.0) | |
Married (N; %) | 71 (78.9) | 30 (63.8) | 0.057 |
Disease duration (months; mean ± SD, range) | 107.5 ± 71.1 (12–336) | 29.7 ± 28.7 (1–108) | <0.0001 |
Cancer types | NA | NA | |
Pancreatic | 16 (34.0) | ||
Lung | 15 (31.2) | ||
Head and neck | 6 (12.8) | ||
Biliary | 4 (8.51) | ||
Esophageal | 3 (6.38) | ||
Gastric | 3 (6.38) | ||
H & Y (mean ± SD) | 2.49 ± 0.82 | NA | NA |
Stage 1 (N; %) | 5 (5.6) | ||
Stage 1.5 | 1 (1.1) | ||
Stage 2 | 36 (40.5) | ||
Stage 2.5 | 23 (25.8) | ||
Stage 3 | 12 (13.5) | ||
Stage 4 | 10 (11.2) | ||
Stage 5 | 2 (2.3) | ||
ECOG | 1.17 ± 0.85 | 1.04 ± 0.81 | 0.40 |
S & E | 80.1 ± 16.5 | 83.0 ± 16.5 | 0.34 |
UPDRS Motor Score (mean ± SD) | 30.9 ± 14.6 | NA | NA |
l‐dopa equivalent dose (mean + SD) | 703.9 ± 482 | NA | NA |
Presence of DBS (N; %) | 10 (11.4) | NA | NA |
MOCA (mean ± SD, range) | 24.9 ± 4.0 (7–30) | NA | NA |
Abbreviation: NA, not applicable.